(USD) | Dec 2022 | Q/Q |
---|---|---|
Revenue | 217.3MM | +3% |
Operating Income | -141.8MM | +19% |
Operating Expenses | 359MM | - |
Net Income | -142.6MM | +17% |
R&D | 87.9MM | +34% |
G&A | 143.8MM | -3% |
Interest Expense | 2.8MM | +18% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
AUSTIN, Texas, July 26, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, for surveillance in Merkel cell carcinoma (MCC). The full study can be found here.
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On July 15, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), executed a sale of 5,496 shares of the company. The transaction was filed on July 17, 2024, as reported in the SEC Filing. Following this transaction, the insider now owns 207,855 shares of Natera Inc.
Artisan Partners, an investment management company, released its “Artisan Global Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The expectation of rate reduction later this year and slowing inflation boosted global markets in Q1. In the first quarter, the fund’s Investor Class ARTHX returned 12.67 %, Advisor […]
AUSTIN, Texas, July 03, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the International Society of Prenatal Diagnosis (ISPD), the conference will take place July 7-10, 2024, in Boston, MA.
Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are...
On July 1, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), executed a sale of 37,500 shares of the company at a price of $108.1 per share. This transaction was filed on July 2, 2024, as reported in the SEC Filing. Following this sale, the insider now owns 213,351 shares of Natera Inc.
AUSTIN, Texas, June 27, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer.
On June 17, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), executed a sale of 6,105 shares of the company. The transaction was filed on June 18, 2024, as reported in the SEC Filing. Following this transaction, the insider now owns 213,351 shares of Natera Inc.
AUSTIN, Texas, June 17, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.